Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
Rectification of internal circulation is expected to improve the pattern of coke supply, and the value restoration of Xuyang Group (01907) is underway.
GMTEight List of A-share restricted sales and lifting restrictions | July 4th
Apple Inc.'s (AAPL.US) price reduction strategy pays off, iPhone sales in China see first quarterly increase in two years.
Rectification of internal circulation is expected to improve the pattern of coke supply, and the value restoration of Xuyang Group (01907) is underway.
GMTEight List of A-share restricted sales and lifting restrictions | July 4th
Apple Inc.'s (AAPL.US) price reduction strategy pays off, iPhone sales in China see first quarterly increase in two years.
